Off-label use of medicine in pediatrics: focus on gastrointestinal diseases

被引:11
|
作者
Karesh, Alyson [1 ]
Tomaino, Juli [2 ]
Mulberg, Andrew E. [2 ]
机构
[1] US FDA, Silver Spring, MD USA
[2] US FDA, Div Gastroenterol & Inborn Errors Prod, Silver Spring, MD USA
关键词
drug development; gastrointestinal; off-label; pediatric; PROTON PUMP INHIBITORS; ADVERSE DRUG-REACTIONS; PRESCRIBING PATTERNS; BOWEL PREPARATION; UNITED-STATES; CHILDREN; INFANTS; GASTROENTEROLOGY; PHARMACOTHERAPY; PERSPECTIVES;
D O I
10.1097/MOP.0b013e328363ed4e
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose of reviewTo provide current information on off-label medication use in pediatric gastroenterology, including a discussion on US legislative efforts to address the issue. Recent findingsMedications used to treat pediatric gastrointestinal illnesses are frequently prescribed off-label. Acid suppressors, antiemetics, laxatives, and antitumor necrosis factor therapies are types of medications frequently used off-label in the pediatric gastroenterology arena. Pediatric studies conducted under US Federal laws are generating much-needed data on the safety and effectiveness of medications used to treat pediatric patients. Moreover, a new US law, the Food and Drug Administration Safety and Innovation Act, may further the development of pediatric medications in part by requiring pediatric-specific study plans earlier in the overall drug development process. As of today, there still are gaps in our knowledge about these medications, including for the treatment of pediatric gastroenterology diseases. SummaryMedications are widely used off-label in pediatrics, including medications intended to treat gastrointestinal diseases, such as antitumor necrosis factor and laxatives. Although legislation is helping to generate and make available important information about pediatric medications, most still do not contain pediatric data. Therefore, providers need to understand the potential risks and benefits of prescribing off-label products to pediatric patients.
引用
收藏
页码:612 / 617
页数:6
相关论文
共 50 条
  • [41] Off-label use of atypical antipsychotics in personality disorders
    Rosenbluth, Michael
    Sinyor, Mark
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (11) : 1575 - 1585
  • [42] Pediatric Off-label Use of Recombinant Factor VIIa
    Alten, Jeffrey A.
    Benner, Kim
    Green, Kelsey
    Toole, Benjamin
    Tofil, Nancy M.
    Winkler, Margaret K.
    PEDIATRICS, 2009, 123 (03) : 1066 - 1072
  • [43] Off-label and unlicensed use of antidotes in paediatric patients
    Lifshitz, M
    Gavrilov, V
    Gorodischer, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (11) : 839 - 841
  • [44] Use of pharmaceuticals 'Off-Label' in the neonate
    Tobin, Joseph R.
    BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY, 2010, 24 (03) : 451 - 460
  • [45] Off-label use of contrast agents
    Reimer, P.
    Vosshenrich, R.
    EUROPEAN RADIOLOGY, 2008, 18 (06) : 1096 - 1101
  • [46] The "Art" of Medicine and The "Smokescreen" of the Randomized Trial Off-Label Use of Vascular Devices
    Ansel, Gary M.
    Jaff, Michael R.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2008, 72 (07) : 998 - 1002
  • [47] Drug treatments in a neonatal setting: focus on the off-label use in the first month of life
    Dessi, Angelica
    Salemi, Claudia
    Fanos, Vassilios
    Cuzzolin, Laura
    PHARMACY WORLD & SCIENCE, 2010, 32 (02): : 120 - 124
  • [48] Two decades of off-label prescribing in children: a literature review
    Balan, Shamala
    Hassali, Mohamed Azmi Ahmad
    Mak, Vivienne S. L.
    WORLD JOURNAL OF PEDIATRICS, 2018, 14 (06) : 528 - 540
  • [49] Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches
    Carnovale, Carla
    Conti, Valentino
    Perrone, Valentina
    Antoniazzi, Stefania
    Pozzi, Marco
    Merlino, Luca
    Venegoni, Mauro
    Clementi, Emilio
    Radice, Sonia
    EUROPEAN JOURNAL OF PEDIATRICS, 2013, 172 (12) : 1679 - 1685
  • [50] Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden
    Vinter, Nicklas
    Linder, Marie
    Andersen, Morten
    Pedersen, Alma B.
    Madsen, Morten
    Schachterle, Stephen E.
    Ataher, Quazi
    Mo, Jingping
    Johnsen, Soren Paaske
    Ehrenstein, Vera
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (06) : 867 - 878